News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

16

March

Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder

14

March

Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D. to Scientific Advisory Board

22

February

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

15

February

Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US

8

February

Israel-Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

31

January

Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

25

January

Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

19

January

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company

17

January

Israel-Based Clearmind Announces Additional Positive Results from the its Pre-Clinical Study for Cocaine Addiction Treatment

10

January

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

5

January

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic-Derived Obesity Treatment in Pre-Clinical Trial

28

December

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

21

December

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute

15

December

Israeli Biotech Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders

13

December

Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100